73 related articles for article (PubMed ID: 18582179)
1. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
[TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
3. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
Wigal SB; Childress AC; Belden HW; Berry SA
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
[TBL] [Abstract][Full Text] [Related]
4. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Pearson DA; Santos CW; Aman MG; Arnold LE; Lane DM; Loveland KA; Mansour R; Ward AR; Casat CD; Jerger S; Schachar RJ; Bukstein OG; Cleveland LA
J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):414-426. PubMed ID: 32644833
[No Abstract] [Full Text] [Related]
5. Adverse Events During Dosing of Delayed-release/Extended-release Methylphenidate: Learnings From the Open-label Phase of a Registration Trial and a Real-world Postmarketing Surveillance Program.
Katzman MA; Otcheretko V; Po MD; Uchida CL; Incledon B
Clin Ther; 2023 Dec; 45(12):1212-1221. PubMed ID: 37770309
[TBL] [Abstract][Full Text] [Related]
6. A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.
Arnold VK; López FA; Childress AC; Po MD; Uchida CL; Cuthbertson L; Sallee FR; Incledon B
J Atten Disord; 2024 Jun; 28(8):1186-1197. PubMed ID: 38600754
[TBL] [Abstract][Full Text] [Related]
7. Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.
Cutler AJ; Kollins SH; Brams MN; Corliss M; Oh C; Braeckman R; Childress AC
Front Psychiatry; 2024; 15():1310483. PubMed ID: 38566957
[TBL] [Abstract][Full Text] [Related]
8. The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder.
Huang HC; Wu LS; Yu SC; Wu BJ; Lua AC; Lee SM; Liu CZ
Psychiatry Investig; 2018 Mar; 15(3):306-312. PubMed ID: 29486545
[TBL] [Abstract][Full Text] [Related]
9. Are all ADHD medications created equal? Exploring the differences that enable evening dosing.
Mattingly GW; Carbray JA; Roy P; López FA
Postgrad Med; 2024 Jun; ():1-12. PubMed ID: 38904469
[TBL] [Abstract][Full Text] [Related]
10. Paternal exposure to a common pharmaceutical (Ritalin) has transgenerational effects on the behaviour of Trinidadian guppies.
De Serrano AR; Hughes KA; Rodd FH
Sci Rep; 2021 Feb; 11(1):3985. PubMed ID: 33597600
[TBL] [Abstract][Full Text] [Related]
11. A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.
Gupta PK; Incledon B; Gobburu JVS; Gomeni R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):132-142. PubMed ID: 37864318
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
[TBL] [Abstract][Full Text] [Related]
14. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
Childress AC; Spencer T; Lopez F; Gerstner O; Thulasiraman A; Muniz R; Post A
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):351-61. PubMed ID: 19702487
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
18. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
Adler LA; Spencer T; McGough JJ; Jiang H; Muniz R
J Atten Disord; 2009 Mar; 12(5):449-59. PubMed ID: 19218542
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
